Optimizing the Clinical Use of Vancomycin

@article{lvarez2016OptimizingTC,
  title={Optimizing the Clinical Use of Vancomycin},
  author={Roc{\'i}o {\'A}lvarez and Luis Eduardo L{\'o}pez Cort{\'e}s and Jos{\'e} Molina and Jos{\'e} Miguel Cisneros and Jer{\'o}nimo Pach{\'o}n},
  journal={Antimicrobial Agents and Chemotherapy},
  year={2016},
  volume={60},
  pages={2601 - 2609}
}
ABSTRACT The increasing number of infections produced by beta-lactam–resistant Gram-positive bacteria and the morbidity secondary to these infections make it necessary to optimize the use of vancomycin. In 2009, the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, and the Society of Infectious Disease Pharmacists published specific guidelines about vancomycin dosage and monitoring. However, these guidelines have not been updated in the past 6 years… Expand
Vancomycin dosing, monitoring and toxicity: Critical review of the clinical practice
TLDR
Controversial aspects related to the efficacy and safety of vancomycin are discussed, correlating them with data available in the literature and identifying knowledge gaps in guide future lines of research. Expand
Vancomycin Dosing and Monitoring: Critical Evaluation of the Current Practice
  • F. Elbarbry
  • Medicine
  • European Journal of Drug Metabolism and Pharmacokinetics
  • 2017
TLDR
Two user-friendly and scientifically based dosing strategies are proposed to improve the efficiency of vancomycin dosing while avoiding the risk of nephrotoxicity and minimizing the cost of therapeutic drug monitoring. Expand
The dosing and monitoring of vancomycin: what is the best way forward?
We have evaluated the literature to review optimal dosing and monitoring of intravenous vancomycin in adults, in response to evolving understanding of targets associated with efficacy and toxicity.Expand
A Prospective Multicenter Clinical Observational Study on Vancomycin Efficiency and Safety With Therapeutic Drug Monitoring.
  • X. Liang, Yaxin Fan, +27 authors H. Zhang
  • Medicine
  • Clinical infectious diseases : an official publication of the Infectious Diseases Society of America
  • 2018
TLDR
It is found no evidence that increasing vancomycin trough concentration to 15-20 mg/L can benefit Chinese patients with complicated infections, and trough concentration is an indicator of nephrotoxicity in the observed population. Expand
Evaluating the Relationship between Vancomycin Trough Concentration and 24-Hour Area under the Concentration-Time Curve in Neonates
TLDR
A retrospective chart review in Singapore hospitals and collected patient characteristics and therapeutic drug monitoring data from neonates on vancomycin therapy over a 5-year period found that steady-state trough concentrations are unlikely to be necessary to achieve an AUC24/MIC of >400, whereas troughs within 10 to 14.9 mg/liter may be more appropriate. Expand
[Directed therapeutic approach to Staphylococcus aureus infections. Clinical aspects of prescription].
TLDR
The development of new antibiotics with activity against MRSA and exploring synergies offer a promising alternative to treatment with vancomycin, and strains with intermediate susceptibility to vancomYcin and heteroresistance have been noted. Expand
Evaluation of the Effectiveness of Dose Individualization to Achieve Therapeutic Vancomycin Concentrations
TLDR
The use of computerized TDM resulted in a higher frequency of therapeutic vancomycin concentrations in a middle‐income setting. Expand
Clinical Outcome and Antimicrobial Therapeutic Drug Monitoring for the Treatment of Infections in Acute Burn Patients.
TLDR
Therapeutic drug monitoring of antimicrobial treatment did not alter the prognosis of these burn patients and more trials are needed to support the use of therapeutic drug monitoring to optimize treatment in burn patients. Expand
Differential Activity of the Combination of Vancomycin and Amikacin on Planktonic vs. Biofilm-Growing Staphylococcus aureus Bacteria in a Hollow Fiber Infection Model
TLDR
Adding vancomycin could reduce possible resistance to amikacin and provide a relevant strategy to prevent the selection of antibiotic-resistant bacteria during treatments, suggesting that, for biofilm-associated infections, the efficacy of this combination would not be much greater than with amkacin monotherapy. Expand
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 92 REFERENCES
Pharmacodynamics of Vancomycin and Other Antimicrobials in Patients with Staphylococcus aureus Lower Respiratory Tract Infections
TLDR
Vancomycin AUC24/MIC values predict time-related clinical and bacteriological outcomes for patients with lower respiratory tract infections caused by methicillin-resistant S. aureus by using data gathered from a therapeutic monitoring environment that observes failures in some cases. Expand
Vancomycin exposure in patients with methicillin-resistant Staphylococcus aureus bloodstream infections: how much is enough?
  • T. Lodise, G. Drusano, +4 authors L. McNutt
  • Medicine
  • Clinical infectious diseases : an official publication of the Infectious Diseases Society of America
  • 2014
TLDR
These findings establish the critical importance of daily AUC/MIC ratios during the first 2 days of therapy, and should be interpreted cautiously and validated in a multicenter randomized trial before adoption into practice. Expand
Efficacy of linezolid versus a pharmacodynamically optimized vancomycin therapy in an experimental pneumonia model caused by methicillin-resistant Staphylococcus aureus.
TLDR
It is supported that a vancomycin AUC₀₁₋₂₄/MIC ratio >400 is necessary to obtain a high bacterial lung reduction in MRSA pneumonia, comparable to that achieved with linezolid and better than that with the low dose of vancomYcin tested. Expand
Vancomycin AUC/MIC Ratio and 30-Day Mortality in Patients with Staphylococcus aureus Bacteremia
TLDR
Clinicians should be aware that the current target AUC/MIC of ≥400 was derived using the reference BMD method, so adjustments to this target need to be made when calculating A UC/MIC ratio using other MIC testing methods. Expand
High-dose vancomycin therapy for methicillin-resistant Staphylococcus aureus infections: efficacy and toxicity.
TLDR
High prevalence of clinical MRSA strains with elevated vancomycin MIC (2 microg/mL) requires aggressive empirical vancomYcin dosing to achieve a trough greater than 15 microg /mL, and Combination or alternative therapy should be considered for invasive infections caused by these strains. Expand
Prospectively Validated Dosing Nomograms for Maximizing the Pharmacodynamics of Vancomycin Administered by Continuous Infusion in Critically Ill Patients
TLDR
These nomograms could be helpful in improving the vancomycin treatment of MRSA infections, especially in the presence of borderline-susceptible pathogens and/or of pathophysiological conditions which may enhance the clearance of vancomYcin, while potentially avoiding the increased risk of nephrotoxicity observed with the use of high intermittent doses of van comycin. Expand
Risk of Vancomycin-induced Nephrotoxicity in the Population With Chronic Kidney Disease
TLDR
There is substantial need for vancomycin pharmacokinetic studies to be performed in the population with CKD to develop an optimum vancomYcin nomogram in these patients to help prevent acute kidney injury and its associated high morbidity, mortality and health care costs. Expand
Basic pharmacodynamics of antibacterials with clinical applications to the use of beta-lactams, glycopeptides, and linezolid.
  • W. Craig
  • Medicine
  • Infectious disease clinics of North America
  • 2003
TLDR
Usual doses of these drugs generally provide adequate plasma concentrations to treat effectively infections in which plasma concentrations are predictive of tissue concentrations, and may give linezolid an advantage over vancomycin in certain respiratory infections. Expand
The pharmacokinetic and pharmacodynamic properties of vancomycin.
  • M. Rybak
  • Medicine
  • Clinical infectious diseases : an official publication of the Infectious Diseases Society of America
  • 2006
TLDR
The pharmacokinetic and pharmacodynamic data related to vancomycin are reviewed and such clinical issues as toxicities and serum concentration monitoring are discussed. Expand
Continuous Infusion Vancomycin for Treatment of Methicillin-Resistant Staphylococcus aureus in Cystic Fibrosis Patients
  • L. Fung
  • Medicine
  • The Annals of pharmacotherapy
  • 2012
TLDR
Three cases of methiciIlin-resistant Staphylococcus aureus in pediatric patients with cystic fibrosis are reported, suggesting that continuous infusion vancomycin is a safe and convenient therapy for MRSA infections. Expand
...
1
2
3
4
5
...